Search

everythinglearnresearchcommunity

for

Search:↓

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Blocking IL-17 signaling may reduce skin inflammation and delay aging.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.

Laser treatment and deroofing are effective options for hidradenitis suppurativa.

Recognizing nail changes helps diagnose and treat non-infectious skin diseases.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Improving access to hidradenitis suppurativa care can reduce social disparities.

Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.

Technology, like mobile apps and AI, is improving skin condition diagnosis and treatment.

A woman developed psoriasis after taking certolizumab pegol, improving after stopping the drug and starting other treatments.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Efalizumab can cause unexpected excessive hair growth.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Biologics for severe asthma have known side effects, but some new risks need more study.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Mogamulizumab can cause hair loss and skin rashes.